Drug Profile


Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; Orelvo; R-1524; Voclera

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Isotechnika
  • Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Paladin Labs
  • Class Antipsoriatics; Ciclosporins; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lupus nephritis
  • No development reported Renal transplant rejection
  • Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 06 Apr 2017 Aurinia Pharmaceuticals completes the phase II AURA-LV trial in Lupus nephritis (Adjunctive treatment) in USA, Bangladesh, Belarus, Bulgaria, China, Ecuador, Guatemala, Georgia, South Korea, Mexico, Philippines, Poland, Russia, Serbia, Singapore, Spain, Sri Lanka, Taiwan, Thailand and Ukraine (PO)
  • 01 Mar 2017 Updated top-line efficacy and adverse events data from the phase IIb AURA-LV trial in Lupus nephritis released by Aurinia Pharmaceuticals
  • 14 Feb 2017 Interim pharmacokinetics data from a phase I trial in Lupus nephritis released by Aurinia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top